Investing in the future
PhySoft is extending the power of its proven propietary technology—currently improving anemia care in dialysis clinics throughout North America—to support individualized dosing for other tough-to-titrate drugs, including narrow therapeutic index (NTI) drugs.
The underlying architecture of PhySoft’s platform supports adaptation to additional clinical indications where patient-specific responses require more precise dosing for better outcomes.
PhySoft’s pipeline represents a growing set of opportunities to apply the company’s proven proprietary technology to additional therapies and patient populations. PhySoft’s strategic collaborations align clinical need, scientific rigor, improved outcomes, and positive impacts on patient care.
Difficult-to-dose and NTI drugs require precise dosing to achieve the intended therapeutic effect, ensure patient stability, and support long-term treatment success.
These are exactly the kinds of therapies where precision dosing can make the greatest impact, improving patient safety, minimizing variability, and reducing unnecessary drug spend.
Pipeline activities reflect a disciplined, evidence-driven approach to ongoing scientific and clinical assessment, feasibility analyses, and prioritization based on clinical complexity and potential benefit.